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Background: Antibiotics, antitussives and mucolytics are commonly used in asthma,
despite limited evidence for their effectiveness. The correlates of use for these
medication classes in asthma were identified.
Methods: Asthma patients aged 18–50 who were regular customers of pharmacies were
included in an observational study. Patients completed a questionnaire, which was
complemented by computerised pharmacy records of previously dispensed medications.
Users of each drug class were compared to non-users in terms of demographics, asthma
characteristics and management.
Results: Among 886 patients (mean age: 37; 55% females), 63.2%, 55.8% and 27.2%,
respectively, were users of antibiotics, mucolytics and antitussives during the previous 12
months. In multivariate analysis, dispensing of 42 units of oral corticosteroids was the
major correlate of receiving antibiotics (OR ¼ 5.47; 95% CI ¼ [3.00–9.97]), mucolytics
(OR ¼ 3.93; 95% CI ¼ [2.38–6.50]) and antitussives (OR ¼ 1.86; 95% CI ¼ [1.18–2.94]).
Compared to well-controlled patients, the probability of receiving antibiotics was
significantly higher for poorly controlled patients (OR ¼ 2.01; 95% CI ¼ [1.28–3.15]).Elsevier Ltd. All rights reserved.
inhaled corticosteroids; LABA, long-acting beta agonists; GP, general practitioner
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France. Tel.: +33 472 129 709; fax: +33 472 129 714.
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L. Laforest et al.58Conclusions: Our results suggest that these drugs are mainly used during asthma
exacerbations. A better understanding of the use of co-medication in asthma is required.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The level of disease control in patients with asthma remains
inadequate despite the emergence of new effective
controller medication.1 Inadequate control is mainly due
to insufficient or inappropriate use of inhaled anti-inflam-
matory therapy.1–3 Adherence to consensus treatment
guidelines for asthma control is generally poor.1
Apart from specific anti-asthma drugs, other therapeutic
classes including antibiotics mucolytics or antitussives are
commonly used in asthma.4 In a previous study, we noticed
that these drug classes were frequently dispensed to asthma
patients in primary care.5 Nevertheless, the factors asso-
ciated with dispensing of such drugs to asthma patients have
not been thoroughly explored. It would be of interest to
investigate whether some correlates could be identified. It
is unclear whether asthma patients who are dispensed these
drug classes differ in their medical characteristics in general
or in their asthma features in particular. Notably, it is of
interest to verify whether patients with poorly controlled
asthma are more likely to receive this therapy. Additionally,
the influence of factors related to asthma management is
not sufficiently known, in particular, whether the dispensing
of these drugs varies according to the type of controller
regimen, or to other medications dispensed to the patient,
such as oral corticosteroids.
The aim of the present study was to identify asthma
patients who are dispensed antibiotics, mucolytics and
antitussives and to evaluate whether determinants of
dispensing can be identified.Methods
Study design
The methodology of the present observational study has
already been presented.6 This was a pharmacy-based
observational study conducted in nine French regions
between November 2003 and June 2004. The protocol was
submitted to and approved by the Commission Nationale
Informatique et Libertes—CNIL, the French data privacy
body.Study population
Asthma patients were consecutively recruited in 348
pharmacies. Pharmacists invited patients to take part in
the study if they were regular users of the pharmacy, aged
18–50, and seeking to fill a prescription for an anti-asthma
medication (R03, Anatomical Therapeutic Chemical Classi-
fication). Before their inclusion, patients were explained the
study by the pharmacists.Data collection
Included patients completed a questionnaire about socio-
demographic and clinical variables, recent asthma symp-
toms and past asthma-related medical resource utilisation
(except medication).
Information on medication dispensed to patients over the
12 months before inclusion were obtained through compu-
terised pharmacy records. Controller medication classes
included inhaled corticosteroids (ICS), long-acting beta
agonists (LABA), LABA-ICS fixed combinations, oral xanthine,
leucotriene receptor antagonists. Non-specific asthma
therapies such as of oral corticosteroids, antibiotics,
mucolytics and antitussives and nasal therapy were also
recorded. Nasal therapy consisted of nasal corticosteroids
and nasal vasoconstrictors. Dispensing of nasal therapy
(nasal vasoconstrictors or nasal corticosteroids) was con-
sidered as a marker of associated rhinitis. Asthma severity
was based on the number of units of oral corticosteroids
dispensed during the past 12 months preceding the survey
(none/1–2/42 units). The units corresponded to the
number of boxes dispensed during the past 12 months. For
each medication class, the number of dispensed units was
available.Level of asthma control
The level of asthma control was determined using the
Asthma Control Test.7 This questionnaire includes items on
the frequency of symptoms, impairment of daily activities
and need for rescue medication during the previous four
weeks. Patients also made a self-assessment of their own
level of control (Table 2). Scoring of asthma control was
based on the sum of counts method.7 Each question included
five response modalities (a–e), classified according to
decreasing level of asthma control. The three last mod-
alities (c, d and e) corresponded to an inadequate level of
control. If patients checked none of the questions as
responses c, d or e, their asthma was considered properly
controlled. If responses c, d or e were checked for one or
two questions, patients had been considered as ‘moderately
uncontrolled’. In all other cases (responses c, d or e checked
for at least three questions), patients were classified as
poorly controlled.Statistical analysis
The analysis was restricted to those patients for whom 12
months of dispensed medication records were available and
for whom at least one controller medication was recorded.
Separate analyses were conducted for each of the three
medication classes of interest, namely antibiotics, mucoly-
tics and antitussives.
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Table 1 Patient characteristics (n ¼ 886).
N %
Age (years)
18–30 237 26.8
31–40 233 26.4
41–50 414 46.8
Female gender 486 55.0
Body mass index 430 kg/m2 113 12.9
Smoking (cigarettes/day)
None 609 69.4
1–9 120 13.7
X10 148 16.9
Anti-asthma controller regimena
Isolated ICS 65 7.3
ICS+LABA (separate medications) 139 15.7
Fixed combination LABA-ICS 541 61.1
Otherb 141 15.9
Oral corticosteroidsa (dispensed units/12 months)
None 476 53.7
1–2 258 29.1
42 152 17.2
Level of asthma control
Well-controlled 224 26.5
Moderately uncontrolled 309 36.5
Poorly controlled 313 37.0
Type of asthma supervision
GP only 263 35.9
GP and specialist 391 53.4
Specialist only 78 10.7
Antibioticsa 560 63.2
Mucolyticsa 494 55.8
Antitussivesa 241 27.2
Associated nasal therapya,c 446 50.3
aIdentified in the computerised pharmacy records during
the previous 12 months.
bThe other category consists of various regimens involving
oral xanthines, cromoglycates, ICS associated with other
drugs than LABA.
cNasal corticosteroids or nasal vasoconstrictors.
Antibiotics, antitussives and mucolytics in asthma 59For each class the level of dispensing was compared to
those of the other two classes, with Spearman rank test.
The association between receiving at least one unit of
each medication class during the previous 12 months and the
different demographic variables, asthma-related character-
istics and disease management variables was assessed by
univariate comparisons using the w2 test and the Wilcoxon
rank test.
Then, multivariate models were computed. For each drug
class, the probability of being dispensed at least one unit
during the past 12 months was studied. All models were
systematically adjusted for age, gender, asthma control,
asthma severity, controller therapy and the type of super-
vision (by GP and/or specialist). Classes for controller
therapy regimens were: ICS alone, combined LABA–ICS
medication alone or associated with other controller(s),
LABA and ICS in two separate medications, and other
regimens. Other potential covariates were included in the
model when they showed a univariate association with the
dependant variable (po0.10).
Results
Patient characteristics
Data could be analysed for 886 patients, whose character-
istics are presented in Table 1. The mean age was 37 years,
and our sample consisted of a majority of women. About a
quarter of the patients could be considered as optimally
controlled. Short-acting beta agonists were commonly
dispensed (73%) and nearly half of the study population
received at least one unit of oral corticosteroids during the
previous 12 months. A minority of patients was supervised
exclusively by a specialist. Most patients were dispensed
LABA–ICS fixed combinations as controller therapy, while
15% received these classes as two separate medications.
About half of the patients received nasal therapy (Table 1).
Dispensing of antibiotics, mucolytics and antitussive
During the previous 12 months, more than half the patients
received antibiotics and mucolytics, whereas more than a
quarter of patients received antitussives (Table 1). Dispen-
sing levels of the three classes of medication were
significantly associated with each other: antibiotics and
mucolytics (r ¼ 0.48, po0.0001; Spearman test), antibiotics
and antitussives (r ¼ 0.22, po0.0001; Spearman test),
antitussives and mucolytics (r ¼ 0.14, po0.0001; Spearman
test). In the study population, 18% of patients were
dispensed both mucolytics and antitussives during the past
12 months.
Correlates of being dispensed antibiotics,
mucolytics and antitussives
Potential determinants of dispensing antibiotics, mucolytics
and antitussives during the 12 months preceding the survey
were evaluated in univariate analysis (Table 2). Women were
more likely to receive antibiotics and antitussives. Signifi-
cant associations were observed for all three medicationclasses with dispensing of nasal medications and oral
corticosteroids. The proportions of patients receiving anti-
biotics, mucolytics and antitussives significantly increased
with decreasing asthma control. Patients supervised exclu-
sively by specialists were less likely to receive these
therapies. Conversely, no significant association was ob-
served between receiving these medication classes and age,
body mass index, and controller therapy regimen. A weak
statistical relationship was observed between smoking
status and being dispensed antibiotics or mucolytics.
The results of the multivariate logistic regression analysis
were generally consistent with those of the univariate
analysis (Table 3). Receiving antibiotics, mucolytics and
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Table 2 Univariate analysis of correlates of dispensing of antibiotics, mucolytics and antitussives (n ¼ 886).
Antibiotics Mucolytics Antitussives
% Users p % Users p % Users p
Overall 63.2 – 55.8 27.2 –
Age (years) 0.76 0.68 0.32
18–30 65.0 57.4 27.0
31–40 61.8 56.6 30.9
41–50 62.8 54.1 25.4
Female gender 67.1 0.01 58.0 0.15 31.3 0.002
Body mass index 430 kg/m2 69.0 0.19 61.9 0.17 29.2 0.58
Smoking (cigarettes/day) 0.04 0.04 0.08
Non-smokers 60.9 53.2 25.6
1–9 65.8 55.8 25.0
X10 71.6 64.9 34.5
Controller regimens 0.54 0.18 0.89
Isolated ICS 60.0 44.6 30.8
ICS+LABA (separate medications) 59.0 53.2 26.6
Fixed combination LABA-ICS (alone or not) 63.8 56.6 27.4
Other 66.7 60.3 25.5
Oral corticosteroids (dispensed units/12 months) 0.0001 0.0001 0.0001
None 49.2 44.3 20.6
1–2 76.4 65.1 32.6
42 84.9 75.7 38.8
Level of asthma control 0.0001 0.0001 0.03
Well-controlled 47.3 44.2 20.1
Moderately uncontrolled 65.7 57.3 28.2
Poorly controlled 72.2 62.9 30.0
Type of asthma supervision
GP only 62.7 0.0001 54.7 0.001 30.4 0.14
GP and specialist 70.6 62.7 29.4
Specialist only 43.6 41.0 19.2
Associated nasal therapy 72.9 0.0001 64.8 0.0001 31.2 0.007
L. Laforest et al.60antitussives were all positively associated to the amount of
oral corticosteroids dispensed. The level of asthma control
was inversely correlated with being dispensed antibiotics
and mucolytics, but not antitussives. For antibiotics, the
poorer the asthma control the higher the probability of
being dispensed these medications. Patients with nasal
therapy were dispensed significantly more antibiotics and
mucolytics. Females received significantly more often
antitussives than males. No significant influences of con-
troller therapy regimen, smoking status, or age were
observed on the outcome variables.Discussion
Antibiotics, mucolytics and antitussives were dispensed to
63.2%, 55.8%, and 27.2% of asthma patients, respectively. In
multivariate analyses, the major correlate of receiving
these drug classes was the level of dispensed oral
corticosteroids. An inadequate level of asthma control wasalso an independent predictor of receiving antibiotics and to
a lesser extent mucolytics, but not antitussives. Being
dispensed nasal therapy was also significantly associated
with receiving antibiotics and mucolytics. In contrast, no
significant effects of controller therapy regimen, age or
smoking status were observed in our data.
Elevated use of antibiotics in asthma has been reported in
numerous European countries,4,8–10 as physicians and more
specifically GPs may overestimate the risk of bacterial
infection.11 Our results are consistent with these findings.
However, there is little evidence that antibiotics benefit
exacerbations of asthma.12 While respiratory infections are
known to trigger asthma exacerbations, most such infections
are of viral origin.13 To date, antibiotics have no established
role in asthma management, except in case of microbial
infectious exacerbations or signs of associated bacterial
sinusitis.14–16 Furthermore, frequent unjustified use of
antimicrobial agents in asthma patients may lead to
increased antibiotic-related adverse events, increased cost
and development of microbial resistance.17
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Table 3 Multivariate analysis of determinants of dispensing of antibiotics, mucolytics and antitussives (n ¼ 697).
Antibiotics Mucolytics Antitussives
OR 95% CI OR 95% CI OR 95% CI
Age (years)
18–30 1.00 – 1.00 – 1.00 –
31–40 1.05 0.67–1.68 1.28 0.82–2.00 1.54 0.97–2.43
41–50 0.87 0.58–1.31 1.02 0.69–1.52 1.04 0.68–1.59
Female gender 1.16 0.82–1.63 1.04 0.74–1.45 1.49 1.05–2.11
Smoking (cigarettes/day)
Non-smokers 1.00 – 1.00 – 1.00 –
1–9 0.97 0.59–1.62 0.92 0.56–1.49 0.77 0.46–1.30
X10 1.10 0.68–1.80 1.25 0.78–2.01 1.27 0.80–2.01
Controller regimens
Isolated ICS 1.00 – 1.00 – 1.00 –
ICS+LABA (separate medications) 1.14 0.53–2.42 1.85 0.89–3.84 0.72 0.34–1.54
Fixed combination LABA-ICSa 1.05 0.55–2.02 1.72 0.92–3.23 0.77 0.41–1.47
Other 1.35 0.63–2.88 2.28 1.09–4.72 0.75 0.36–1.57
Oral corticosteroids (dispensed units/12 months)
None 1.00 – 1.00 – 1.00 –
1–2 2.19 1.47–3.27 2.17 1.48–3.19 1.44 0.96–2.14
42 5.47 3.00–9.97 3.93 2.38–6.50 1.86 1.18–2.94
Level of asthma control
Well-controlled 1.00 – 1.00 – 1.00 –
Moderately uncontrolled 1.73 1.13–2.66 1.81 1.18–2.77 1.28 0.80–2.03
Poorly controlled 2.01 1.28–3.15 1.65 1.06–2.55 1.23 0.77–1.98
Type of asthma supervision
GP only 1.00 – 1.00 – 1.00 –
GP and specialist 1.27 0.87–1.84 1.24 0.87–1.78 0.93 0.64–1.34
Specialist only 0.47 0.26–0.83 0.55 0.31–0.98 0.60 0.30–1.16
Associated nasal therapy 1.84 1.30–2.61 2.21 1.58–3.08 1.20 0.85–1.70
Data are presented as odds ratios (OR) with 95% confidence intervals (CI).
aAlone or associated with another controller.
Antibiotics, antitussives and mucolytics in asthma 61Similarly, our data confirm the persistence of regular
prescription of antitussives and mucolytics in asthma.4,10,18
Unexpectedly, a substantial proportion of patients were
dispensed both antitussives and mucolytics in the previous
year (18%). Although our data did not enable us to
demonstrate formally a concomitant use of both therapies,
a salient significant positive association was observed
between dispensing levels of the two drug classes (Spearman
test po0.0001). This finding is of concern, as this associa-
tion could be considered as physiologically illogical.
Few data are available regarding the use of mucolytics
and antitussives in asthma, although there is insufficient
evidence to support the beneficial effect of mucolytics in
asthma.14,19 In addition, inhaled mucolytics may worsen
cough and airflow limitation in case of severe exacerba-
tion.14 According to current consensus guidelines, antitus-
sives have no place in the therapy of asthma, and some may
even be contraindicated.
In multivariate analysis, an association was observed
between asthma control and being dispensed antibiotics andmucolytics. For antibiotics, the odds ratio for dispensing was
inversely related to asthma control levels. In contrast, no
association between dispensing antitussives and asthma
control was observed.
Likewise, for all three drug classes, the strongest
association was observed for the amount of dispensed oral
corticosteroids. The relationships identified with both oral
corticosteroids and asthma control support the hypothesis of
more specific use of antibiotics, mucolytics and antitussives
during asthma exacerbations or in patients with more severe
asthma. These findings are in line with those of previous
surveys, that identified a higher use of antibiotics during
exacerbations, notably in primary care.9,20,21 A previous
study also reported the common use of antitussives during
asthma exacerbations.18
Although this finding needs direct confirmation, the
strong association identified between antibiotics and oral
corticosteroids suggests concomitant use of these drugs. A
recent study concluded that the addition of antibiotics
to oral corticosteroids in patients with severe asthma
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L. Laforest et al.62exacerbation had no additional beneficial effect on reactive
airway symptoms.22
A number of other variables were associated with
dispensing of these three drug classes. The higher level of
dispensing of antibiotics and mucolytics in patients treated
with nasal therapy suggest the use for rhinitis-related
symptoms. Women were more likely receive antitussives.
This finding is consistent with a recent study reporting that
women with chronic cough had greater impairment of their
quality of life, and were more inclined to seek medical
attention.23 Again, this hypothesis requires confirmation.
The higher extent of use of these drug classes in primary
care has already been discussed in a previous article.5
No major association was identified with the type of
asthma controller therapy regimen. The significantly in-
creased probability of receiving mucolytics in patients
treated with ‘other’ regimens cannot be easily interpreted
as this category consists of various different regimens, and
requires confirmation.
The general limitations of the present study have already
been discussed elsewhere.6 The main specific limitation was
the absence of data on patients’ co-morbid diagnoses, or on
the reasons of the prescriptions. Even though our results
suggest a higher dispensing of antibiotics, expectorants and
antitussives during asthma exacerbation, caution is needed.
Indeed, it cannot be excluded that some of these prescrip-
tions may have been induced by co-morbid diagnoses, such
as sinusitis, bacterial infection or chronic bronchitis, or
common cold. Furthermore, some of these potentially
associated diagnoses, notably infections, may contribute
to trigger asthma exacerbations.
Some other points merit discussion. Firstly, our data on
treatments were based on dispensed medications, which
may not reflect the actual use of the drugs by patients.
Additionally, the precise dosages of dispensed drugs were
not available. The design of our observational survey did not
enable us to determine causal relationships. This was
notably the case for the statistical associations observed
with the dispensing level oral corticosteroids, despite the
presence of a clear dose–effect pattern.
Our assessment of asthma control was derived from the
‘sum of counts’ method,7 in order to construct three classes
of control and to identify potential dose–effect patterns.
When the sum score method was used, a significant effect
was still observed for antibiotics (OR ¼ 1.52, 95%
CI ¼ [1.06–2.15]). Finally, in order to control for potential
bias due to patients with chronic obstructive pulmonary
disease, the analysis was repeated only in patients not older
than 40. Statistical associations with dispensing more than
two prescriptions of oral corticosteroids persisted:
OR ¼ 7.6, 95% CI ¼ [3.1–18.9], OR ¼ 3.7, 95% CI ¼ [1.9–7.4]
and OR ¼ 2.5, 95% CI ¼ [1.3–4.5] for antibiotics, mucolytics
and antitussives, respectively. This suggests that, if such
bias cannot be excluded; however, it may not affect our
finding to a great extent.
Our findings have several implications. While a substantial
change in anti-asthma controller therapy has occurred
during the past decade, frequent recourse to antibiotics,
mucolytics and antitussives persists in asthma therapy in
France, despite the lack of evidence for clinical benefit.
In order to improve the quality of asthma care, the
circumstances and motivations behind prescription of thesedrugs to patients with asthma need to be elucidated, as do
prescribers’ perceptions of the role of these medications in
asthma. Treatment goals in terms of asthma exacerbation
and control of infections or other co-morbid conditions need
to be identified. A specific epidemiological study would be
helpful in achieving this objective. Such a study may be
complemented by interviews with prescribers. The con-
comitant association of mucolytics and antitussives should
also be verified. Finally, it may be of interest to investigate
whether these drug classes are prescribed as a substitute for
inhaled corticosteroids.
Education campaigns focused on physicians may help to
increase awareness of optimal ways to approach the
treatment of asthma. Such education should emphasise
the need for regular use of inhaled corticosteroids and on
the lack of evidence for any benefit associated with the use
of antibiotics, mucolytics and antitussives in routine
management of asthma. Moreover, pharmacists could help
identify asthma patients who receive frequent prescriptions
of such drugs and document the circumstances of their use,
particularly in poorly controlled patients or those with
severe asthma.
In conclusion, our data indicate that in spite of the
absence of documented clinical benefit antibiotics, muco-
lytics and antitussives are more specifically dispensed during
asthma exacerbation or to severe asthma patients, maybe at
the expense of controller therapy. Education programmes
are needed to bring drug prescription patterns closer into
line with consensus treatment guidelines.Acknowledgements
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